Evaluating potential checkpoint inhibitor therapies in vitro depends on models that mimic T cell activation in the tumor microenvironment. Mixed lymphocyte reaction (MLR) assays provide this critical context, but extracting actionable data during analysis often creates a workflow bottleneck.
Conventional analysis forces labs to run separate assays to measure proliferation, cytokine release, and activation marker expression. Because each readout requires its own assay, data are extracted from different sample populations at different time points, increasing labor and variance.
This application note documents a high-throughput screening cytometry workflow for analyzing MLR-based checkpoint inhibitor response from a single assay plate. By capturing proliferation, activation markers, and cytokine profiles together, the protocol supports a more complete view of immune response.
Download this application note to explore
- How one-way and two-way MLR assays support checkpoint inhibitor evaluation
- Methods for multiplex analysis of proliferation, activation markers, and cytokines
- How donor differences shape T cell activation
- Checkpoint inhibitor antibody responses alone versus in combination
